CEMIP2 and prostate carcinoma: In Irie et al., transmembrane protein 2 (TMEM2), the only known transmembrane hyaluronidase, has been reported to degrade HA in osteosarcoma, breast, and prostate cancers, thereby remodeling the surrounding microenvironment in a manner that is favorable for their adhesion, migration, and invasion.